Your browser doesn't support javascript.
How can we improve the safe use of herbal medicine and other natural products? A clinical pharmacologist mission.
Enioutina, Elena Y; Job, Kathleen M; Krepkova, Lubov V; Reed, Michael D; Sherwin, Catherine M.
  • Enioutina EY; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine , Salt Lake City, UT, USA.
  • Job KM; Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine , Salt Lake City, UT, USA.
  • Krepkova LV; Toxicology Department, Center of Medicine, All-Russian Research Institute of Medicinal and Aromatic Plants (VILAR) , Moscow, Russia.
  • Reed MD; School of Medicine, Case Western Reserve University , Cleveland, OH, USA.
  • Sherwin CM; Department of Pediatrics, Wright State University Boonshoft School of Medicine/Dayton Children's Hospital , Dayton, OH, USA.
Expert Rev Clin Pharmacol ; : 1-10, 2020 Aug 10.
Artigo em Inglês | MEDLINE | ID: mdl-32730191


Three major classes of natural products (NPs) for medicinal purposes or improving wellbeing are generally available in the US conventional drugs of herbal origin, botanical drugs, and dietary supplements (DSs). Consumer consumption of DSs is growing annually. The U.S. FDA regulates conventional and botanical drugs for safety and efficacy; however, DSs are minimally regulated. AREAS COVERED This article will i) highlight the importance of NP as a significant source of prescription drugs; ii) discuss differences in the regulation of conventional drugs of NP product, botanical drugs, and DSs; iii) discuss the safety and efficacy of DSs and iv) make recommendations for improvement of safety for minimally regulated NPs. EXPERT OPINION Toxicities associated with the use of NPs, including vitamins and DSs, are mainly due to excessive use and interactions with conventional drug(s) and may represent challenges for clinicians. Conventional and botanical-based prescription drugs are rarely associated with unknown toxicities. However, DSs are minimally regulated and can produce severe adverse effects. We believe that clinical pharmacologists can have a role in developing criteria for DS safety analysis. There is also the potential for a standardized NP stewardship program(s) and the development of NP policies and practices nationally and globally.





Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Idioma: Inglês Revista: Expert Rev Clin Pharmacol Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Estados Unidos